Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
about
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseInhaled corticosteroids for stable chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary diseaseCOPD immunopathologyGlucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary diseaseCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateImpact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD.Blood and sputum eosinophils in COPD; relationship with bacterial load.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Immunological Features of Chronic Obstructive Pulmonary Disease (COPD) Induced by Indoor Pollution and Cigarette SmokeSalmeterol combined with fluticasone propionate improved COPD in patients during stable stage.Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.Glucocorticosteroids: current and future directions.Steroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokers.Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trialEffects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPDErythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation.Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocolTriple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treEffects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis.A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians.Expression levels of induced sputum IL-8 and IL-10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude.Treating patients with respiratory disease who smoke.Is there a role for antiinflammatory treatment in COPD?Inhaled corticosteroids in chronic obstructive pulmonary disease: a review.Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture methodologyThe effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.Resolution of cell-mediated airways diseases.Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial.
P2860
Q24197853-E3BD793F-8F90-4BF1-94A7-36030B9CFAAAQ24197989-E88EFF7C-7979-4539-B75C-EE5EF5097F77Q24199130-DE149EE3-DD84-4A68-8F08-CA22972F57CDQ24200446-0F44ECB5-4B54-4B7D-A36C-B9D46EF9F1F5Q24202092-ABC32696-E02A-4B4B-9AA9-2F1A8D98C30EQ24202510-03679552-DA6E-4F72-B933-8F22E7A3D239Q24243515-D96D5A1F-0ABF-40D0-9648-111287362A42Q24243564-F61D03A8-16BE-466E-A396-95C7475C3983Q24243613-255752D1-E47B-49E6-9D04-F5C60E183797Q26749575-E4C29D48-A744-4893-9618-ED40534A6D50Q28761895-C845344B-42DB-42C1-9843-64A900D9DEBFQ33591899-84A75A04-37A5-4D97-8079-E2E3B6D416B1Q33613164-5C270391-B338-4770-B42C-4A6152A94B40Q33651114-7DD7B21F-D811-4653-8572-A4137CAD1107Q34065276-68648FC2-9768-40D9-9C61-6F93F7DD83ABQ34126693-DCB97C9F-B54C-44D4-9D5A-4045EC437FD8Q34415156-1AD02D04-7ABF-4D54-BC20-3B09ED5273A0Q34738020-82A15926-0A51-481C-A920-D25906A8E383Q34903070-8DE27612-CFEB-4A97-9B2A-9BADE42E0A25Q35088162-53AEE6AB-1E96-49D6-9C02-A7FAF7D224D0Q35531955-1CA6F617-64D0-4C16-9C35-464D2E003916Q35602749-4651C610-1F6E-4AB9-97BA-B23709EAE69BQ35747036-AF4CF07B-FAF4-4D88-849A-4AD52E11F072Q35747040-1C7B11DA-EB60-428A-AF66-5BC10F668D42Q36020700-F64EAEBB-F0B1-4181-80EF-169AC5C00E28Q36086153-B569C850-A51E-4F8F-B96F-D4A383EC569AQ36265120-2C2BA129-06DB-4E7A-9A16-A4674A0CF317Q36283909-6B801D2C-8C40-4808-9E27-FA786BFB49D7Q36510045-4837867E-B09C-4232-AB6A-598727BE3D32Q36514081-E488DA37-6D4F-4CCA-A2B7-F96339013E12Q37207272-E6B42DB2-59C0-4920-9253-43FF2FB5D178Q37362600-F2163914-2533-4352-B091-3C4E896BF018Q37622935-3EB61AB9-4E22-4215-ABF4-E9C6AFB7CF85Q37681569-668B7A2B-8620-4FF9-90EF-5EA1C3540F0FQ37729297-623B281B-15AA-4393-B009-A197181D09D8Q37731160-D0275CE6-2483-4466-A17B-E6264A50CD42Q37748948-EAD16AC6-5C2F-405B-A5B3-99407FDB1D2BQ37764375-99E903EA-8D53-41D8-B603-521BF25BD3B3Q38125210-DD052EFC-2CF2-42E8-9B1E-ECC2FC677CCAQ38442260-E0B4F057-F295-4088-8936-CC887E3F5CE6
P2860
Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@ast
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@en
type
label
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@ast
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@en
prefLabel
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@ast
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@en
P2093
P2860
P356
P1433
P1476
Effect of salmeterol/fluticaso ...... a randomised controlled trial.
@en
P2093
Francois Maltais
Jean Bourbeau
Pota Christodoulopoulos
Ronald Olivenstein
Yasuhiro Yamauchi
P2860
P304
P356
10.1136/THX.2006.071068
P407
P577
2007-06-08T00:00:00Z